CD1530: A promising oral cavity cancer prevention approach using a RAR gamma activator
Official title: CD 1530, an RAR Gamma Agonist for Oral Cavity Squamous Cell Carcinoma Prevention
Funded at Weill Medical Coll of Cornell Univ · NIH-11403870 · Data updated 2026-11-12
A researcher is testing a drug that activates a receptor in the lining of the mouth to help prevent squamous cell cancers before they start or spread.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 11, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $457,226 |
| NIH project number | 5R01CA270248-04 |
| Project ID | NIH-11403870 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at high risk for oral cavity or esophageal squamous cell carcinomas, such as those with premalignant changes or strong risk factors.
✕Less likely to help
Patients without higher-than-average risk or with existing advanced disease may not directly benefit from a prevention-focused intervention.
What this research studies
This project studies whether a selective RAR gamma agonist called CD1530 can prevent oral cavity cancers in people at risk, based on encouraging animal data. It focuses on how activating this receptor may change gene activity in the mouth lining to stop cancer from forming or recurring. The study uses a preclinical/early clinical framework to explore the drug’s effects on tumor formation and field cancerization in head and neck tissues. If successful, it could lead to new prevention options for individuals at high risk of oral and related cancers.
Why it matters
Potential benefit: If successful, this work could lead to a new prevention strategy that reduces the risk of developing oral cavity and related head and neck cancers.
How similar studies have gone: Previous studies in mouse models showed reduced carcinoma development with CD1530, supporting potential relevance to humans.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Gudas, Lorraine J — Weill Medical Coll of Cornell Univ
- Study coordinator: Gudas, Lorraine J
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.